BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 7495543)

  • 61. Use of Reporter Genes in the Generation of Vaccinia Virus-Derived Vectors.
    Al Ali S; Baldanta S; Fernández-Escobar M; Guerra S
    Viruses; 2016 May; 8(5):. PubMed ID: 27213433
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Generation of Recombinant Vaccinia Viruses.
    Wyatt LS; Earl PL; Moss B
    Curr Protoc Microbiol; 2015 Nov; 39():14A.4.1-14A.4.18. PubMed ID: 26528782
    [TBL] [Abstract][Full Text] [Related]  

  • 63. A marker-free system for highly efficient construction of vaccinia virus vectors using CRISPR Cas9.
    Yuan M; Gao X; Chard LS; Ali Z; Ahmed J; Li Y; Liu P; Lemoine NR; Wang Y
    Mol Ther Methods Clin Dev; 2015; 2():15035. PubMed ID: 26417609
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Lineage specific antigenic differences in porcine torovirus hemagglutinin-esterase (PToV-HE) protein.
    Pignatelli J; Alonso-Padilla J; Rodríguez D
    Vet Res; 2013 Dec; 44(1):126. PubMed ID: 24364900
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Clinical value of ELISA-MPT64 for the diagnosis of tuberculous pleurisy.
    Liu Z; Zhu C; Yang H; Hu H; Feng Y; Qin L; Cui Z; Bi A; Zheng R; Jin R; Fan L; Hu Z
    Curr Microbiol; 2012 Sep; 65(3):313-8. PubMed ID: 22674175
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Evaluation of the clinical value of ELISA based on MPT64 antibody aptamer for serological diagnosis of pulmonary tuberculosis.
    Zhu C; Liu J; Ling Y; Yang H; Liu Z; Zheng R; Qin L; Hu Z
    BMC Infect Dis; 2012 Apr; 12():96. PubMed ID: 22520654
    [TBL] [Abstract][Full Text] [Related]  

  • 67. A selectable and excisable marker system for the rapid creation of recombinant poxviruses.
    Rintoul JL; Wang J; Gammon DB; van Buuren NJ; Garson K; Jardine K; Barry M; Evans DH; Bell JC
    PLoS One; 2011; 6(9):e24643. PubMed ID: 21931792
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Expanding the repertoire of Modified Vaccinia Ankara-based vaccine vectors via genetic complementation strategies.
    Garber DA; O'Mara LA; Zhao J; Gangadhara S; An I; Feinberg MB
    PLoS One; 2009; 4(5):e5445. PubMed ID: 19421328
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Residues in the stalk domain of the hendra virus g glycoprotein modulate conformational changes associated with receptor binding.
    Bishop KA; Hickey AC; Khetawat D; Patch JR; Bossart KN; Zhu Z; Wang LF; Dimitrov DS; Broder CC
    J Virol; 2008 Nov; 82(22):11398-409. PubMed ID: 18799571
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Cell surface expression of the vaccinia virus complement control protein is mediated by interaction with the viral A56 protein and protects infected cells from complement attack.
    Girgis NM; Dehaven BC; Fan X; Viner KM; Shamim M; Isaacs SN
    J Virol; 2008 May; 82(9):4205-14. PubMed ID: 18287241
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Co-expressing GP5 and M proteins under different promoters in recombinant modified vaccinia virus ankara (rMVA)-based vaccine vector enhanced the humoral and cellular immune responses of porcine reproductive and respiratory syndrome virus (PRRSV).
    Zheng Q; Chen D; Li P; Bi Z; Cao R; Zhou B; Chen P
    Virus Genes; 2007 Dec; 35(3):585-95. PubMed ID: 17922181
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Direct comparison of antigen production and induction of apoptosis by canarypox virus- and modified vaccinia virus ankara-human immunodeficiency virus vaccine vectors.
    Zhang X; Cassis-Ghavami F; Eller M; Currier J; Slike BM; Chen X; Tartaglia J; Marovich M; Spearman P
    J Virol; 2007 Jul; 81(13):7022-33. PubMed ID: 17409140
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Identification of Hendra virus G glycoprotein residues that are critical for receptor binding.
    Bishop KA; Stantchev TS; Hickey AC; Khetawat D; Bossart KN; Krasnoperov V; Gill P; Feng YR; Wang L; Eaton BT; Wang LF; Broder CC
    J Virol; 2007 Jun; 81(11):5893-901. PubMed ID: 17376907
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Quantitative analysis of Nipah virus proteins released as virus-like particles reveals central role for the matrix protein.
    Patch JR; Crameri G; Wang LF; Eaton BT; Broder CC
    Virol J; 2007 Jan; 4():1. PubMed ID: 17204159
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Vaccine properties of a novel marker gene-free recombinant modified vaccinia Ankara expressing immunodominant CMV antigens pp65 and IE1.
    Wang Z; La Rosa C; Li Z; Ly H; Krishnan A; Martinez J; Britt WJ; Diamond DJ
    Vaccine; 2007 Jan; 25(6):1132-41. PubMed ID: 17049414
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Characterization of a vaccinia virus mutant with a deletion of the D10R gene encoding a putative negative regulator of gene expression.
    Parrish S; Moss B
    J Virol; 2006 Jan; 80(2):553-61. PubMed ID: 16378957
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Immune responses against a single CD8+-T-cell epitope induced by virus vector vaccination can successfully control Trypanosoma cruzi infection.
    Miyahira Y; Takashima Y; Kobayashi S; Matsumoto Y; Takeuchi T; Ohyanagi-Hara M; Yoshida A; Ohwada A; Akiba H; Yagita H; Okumura K; Ogawa H
    Infect Immun; 2005 Nov; 73(11):7356-65. PubMed ID: 16239534
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Receptor binding, fusion inhibition, and induction of cross-reactive neutralizing antibodies by a soluble G glycoprotein of Hendra virus.
    Bossart KN; Crameri G; Dimitrov AS; Mungall BA; Feng YR; Patch JR; Choudhary A; Wang LF; Eaton BT; Broder CC
    J Virol; 2005 Jun; 79(11):6690-702. PubMed ID: 15890907
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Protection of rhesus monkeys against infection with minimally pathogenic simian-human immunodeficiency virus: correlations with neutralizing antibodies and cytotoxic T cells.
    Quinnan GV; Yu XF; Lewis MG; Zhang PF; Sutter G; Silvera P; Dong M; Choudhary A; Sarkis PT; Bouma P; Zhang Z; Montefiori DC; Vancott TC; Broder CC
    J Virol; 2005 Mar; 79(6):3358-69. PubMed ID: 15731230
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Recombinant modified vaccinia virus Ankara expressing a soluble form of glycoprotein B causes durable immunity and neutralizing antibodies against multiple strains of human cytomegalovirus.
    Wang Z; La Rosa C; Maas R; Ly H; Brewer J; Mekhoubad S; Daftarian P; Longmate J; Britt WJ; Diamond DJ
    J Virol; 2004 Apr; 78(8):3965-76. PubMed ID: 15047812
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.